LABT
Lakewood-Amedex Biotherapeutics Inc. Common Stock
NASDAQ: LABT · HEALTHCARE · BIOTECHNOLOGY
$0.36
-9.06% today
Updated 2026-11-12
Market cap
$985790.00
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-8.83
Dividend yield
—
52W range
$0 – $10
Volume
18.3M
WallStSmart proprietary scores
26
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C6.0
Quality
B3.5
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
-186.0
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →259 stocks currently score above 75
Price targets
Analyst target
$7.50
+1987.97%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.02x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -186.00 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-2.10M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-8.28M | $-4.86M | $-3.85M | $-3.77M |
| EPS | — | — | — | $-8.83 |
| Free cash flow | $-6.82M | $-5.73M | $-1.94M | $-2.10M |
| Profit margin | — | — | — | — |
Peer comparison
Smart narrative
Lakewood-Amedex Biotherapeutics Inc. Common Stock trades at $0.36. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -186.00, it sits in the distress.
Frequently asked questions
What is Lakewood-Amedex Biotherapeutics Inc. Common Stock's stock price?
Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) trades at $0.36.
Is Lakewood-Amedex Biotherapeutics Inc. Common Stock overvalued?
Lakewood-Amedex Biotherapeutics Inc. Common Stock carries a Smart Value Score of 26/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT)?
The 12-month analyst consensus target is $7.50, about 1988.0% above the current $0.36. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Lakewood-Amedex Biotherapeutics Inc. Common Stock's Altman Z-Score is -186.00, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE—
Beta—
50D MA$1.15
200D MA$6.93
Shares out0.00B
Float0.00B
Short ratio—
Avg volume18.3M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—